Yeung Andy Wai Kan, Atanasov Atanas G, Sheridan Helen, Klager Elisabeth, Eibensteiner Fabian, Völkl-Kernsock Sabine, Kletecka-Pulker Maria, Willschke Harald, Schaden Eva
Oral and Maxillofacial Radiology, Applied Oral Sciences and Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.
Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Vienna, Austria.
Front Pharmacol. 2021 Jan 14;11:587526. doi: 10.3389/fphar.2020.587526. eCollection 2020.
Open innovation in medical and pharmaceutical research has grown steadily over the last decade. However, the performance of the published literature in terms of the scientific impact and gaining social media attention remains largely unexplored. The scientific literature of open innovation was examined by means of bibliometric analyses to identify the most prolific authors, organizations, countries, journals, research areas, and recurring terms. By accessing the Web of Science Core Collection and Altmetric electronic databases, citation-related and Altmetric data were evaluated. Public-private partnerships and a selection of newly introduced potential novel drugs in the analyzed publications were identified. North America and Europe were the major literature contributors. Research outputs were mainly published in journals focused on business and economics, pharmacology and pharmacy, and engineering. Many pharmaceutical and biotechnological companies contributed to the analyzed publications, with higher mean citation counts and social media attention (Altmetric score) than nonindustry articles. Public-private partnerships fostered financial support, sharing of expertise and intellectual property, and research collaborations. In summary, open innovation might serve as a powerful strategy to both benefit the involved industry entities and accelerate the development of solutions and products for the betterment of human health.
在过去十年中，医学和制药研究领域的开放式创新稳步发展。然而，已发表文献在科学影响力和获得社交媒体关注方面的表现仍 largely unexplored。通过文献计量分析对开放式创新的科学文献进行了研究，以确定最多产的作者、组织、国家、期刊、研究领域和重复出现的术语。通过访问科学网核心合集和Altmetric电子数据库，对与引文相关的数据和Altmetric数据进行了评估。确定了公私合作伙伴关系以及分析出版物中一些新引入的潜在新药。北美和欧洲是主要的文献贡献地区。研究成果主要发表在专注于商业与经济、药理学与药剂学以及工程学的期刊上。许多制药和生物技术公司为分析的出版物做出了贡献，其平均被引次数和社交媒体关注度（Altmetric评分）高于非行业文章。公私合作伙伴关系促进了资金支持、专业知识和知识产权的共享以及研究合作。总之，开放式创新可能是一种强大的策略，既能使相关行业实体受益，又能加速解决方案和产品的开发，以改善人类健康。
